Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | May 26, 2021 | May 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date May 26, 2021 · Filed May 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,800 |
Reported balance
After 2021-05-26 transaction · row 1
1 source rowRow 1 · 2021-05-26 · Grant · Acquired 4,700 · Balance 37,800 F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.86 · Expires 2031-05-25 | Direct | 7,800 |
Reported balance
After 2021-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-26 · Grant · Acquired 7,800 · Balance 7,800 F2: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
F2: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2018 Filed Mar 16, 2018 22:01 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,900 | $52.21 | $151,409.00 |
DisclosureSEC source: 0001209191-18-020340 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,100 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F2 · price: The shares were sold at prices ranging from $51.65 to $52.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 22:01 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 4,000 | $2.90 | $11,600.00 |
DisclosureSEC source: 0001209191-18-020340 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-010939 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,100 | $56.25 | $61,875.00 |
DisclosureSEC source: 0001209191-18-010939 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F3 · price: The shares were sold at prices ranging from $56.02 to $56.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,900 | $55.56 | $272,244.00 |
DisclosureSEC source: 0001209191-18-010939 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,100 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F2 · price: The shares were sold at prices ranging from $55.00 to $55.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $2.90 | $17,400.00 |
DisclosureSEC source: 0001209191-18-010939 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2018 Filed Jan 20, 2018 01:22 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-004658 · doc4.xml · derivative · entry 4 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| January 18, 2018 Filed Jan 20, 2018 01:22 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 600 | $47.99 | $28,794.00 |
DisclosureSEC source: 0001209191-18-004658 · doc4.xml · nonDerivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F3 · price: The shares were sold at prices ranging from $47.90 to $48.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2018 Filed Jan 20, 2018 01:22 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,400 | $47.31 | $255,474.00 |
DisclosureSEC source: 0001209191-18-004658 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,600 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F2 · price: The shares were sold at prices ranging from $46.90 to $47.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 18, 2018 Filed Jan 20, 2018 01:22 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $2.90 | $17,400.00 |
DisclosureSEC source: 0001209191-18-004658 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 00:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $42.80 | $85,600.00 |
DisclosureSEC source: 0001209191-17-066535 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 00:11 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-17-065514 · doc4.xml · derivative · entry 3 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 00:11 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 12,000 | $44.45 | $533,400.00 |
DisclosureSEC source: 0001209191-17-065514 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 F1 · price: The shares were sold at prices ranging from $44.40 to $44.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 00:11 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $2.90 | $34,800.00 |
DisclosureSEC source: 0001209191-17-065514 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 00:43 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $46.65 | $93,300.00 |
DisclosureSEC source: 0001209191-17-061886 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 22:18 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $52.24 | $104,480.00 |
DisclosureSEC source: 0001209191-17-057336 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F2 · price: The shares were sold at prices ranging from $54.00 to $54.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $52.55 | $105,100.00 |
DisclosureSEC source: 0001209191-17-053528 · doc4.xml · nonDerivative · entry 2 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
| August 17, 2017 Filed Sep 20, 2017 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $40.74 | $81,480.00 |
DisclosureSEC source: 0001209191-17-053528 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. F2 · price: The shares were sold at prices ranging from $40.70 to $40.7501. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 20:26 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $33.45 | $66,900.00 |
DisclosureSEC source: 0001209191-17-045510 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:50 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $28.50 | $57,000.00 |
DisclosureSEC source: 0001209191-17-040904 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 22:39 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001209191-17-038999 · doc4.xml · derivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable quarterly over one year measured from June 7, 2017. Read SEC document |
| May 16, 2017 Filed May 18, 2017 01:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $27.40 | $54,800.00 |
DisclosureSEC source: 0001209191-17-033461 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 22:11 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $25.25 | $50,500.00 |
DisclosureSEC source: 0001209191-17-027537 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
| March 15, 2017 Filed Feb 15, 2018 01:06 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $25.20 | $50,400.00 |
DisclosureSEC source: 0001209191-18-010199 · doc5.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $24.45 | $48,900.00 |
DisclosureSEC source: 0001209191-17-012205 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
| January 19, 2017 Filed Jan 21, 2017 01:34 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $24.90 | $49,800.00 |
DisclosureSEC source: 0001209191-17-005002 · doc4.xml · nonDerivative · entry 1 Kurkijarvi Kalevi · CIK 0001621333 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 F1 · kind: Shares sold pursuant to a 10b5-1 Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.